249 related articles for article (PubMed ID: 33519217)
1. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
Freeman L; Kee A; Tian M; Mehta R
Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
5. The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis.
Pardo G; Pineda ED; Ng CD; Sheinson D; Bonine NG
J Health Econ Outcomes Res; 2022; 9(1):111-116. PubMed ID: 35586512
[No Abstract] [Full Text] [Related]
6. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J; Marshall TS; Ye X
Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
[TBL] [Abstract][Full Text] [Related]
7. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
8. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
10. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
[TBL] [Abstract][Full Text] [Related]
12. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
Mardan J; Hussain MA; Allan M; Grech LB
J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
[No Abstract] [Full Text] [Related]
13. Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
Zhu W; Tang X; Heyman RA; Cai T; Suh K; Seeger JD; Xia Z
Neurol Ther; 2022 Sep; 11(3):1147-1165. PubMed ID: 35598225
[TBL] [Abstract][Full Text] [Related]
14. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Moccia M; Affinito G; Berera G; Marrazzo G; Piscitelli R; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
J Neurol; 2022 Dec; 269(12):6504-6511. PubMed ID: 35953597
[TBL] [Abstract][Full Text] [Related]
15. Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis.
Pardo G; Pineda ED; Ng CD; Bawa KK; Sheinson D; Bonine NG
Neurol Ther; 2022 Mar; 11(1):337-351. PubMed ID: 35020156
[TBL] [Abstract][Full Text] [Related]
16. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study.
Moccia M; Affinito G; Marrazzo G; Ciarambino T; Di Procolo P; Confalonieri L; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
Neurol Int; 2024 Mar; 16(2):394-405. PubMed ID: 38668126
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Lahoz R; Reynolds T; Korn JR
Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
[TBL] [Abstract][Full Text] [Related]
19. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
[TBL] [Abstract][Full Text] [Related]
20. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]